-
Sep 22 |
Diagnostics World News | Epigenetic instability, a measure of the chaotic nature of methylation in specific regions of circulating cell-free DNA (cfDNA), has emerged as a promising new approach for early cancer detection. In a recent proof-of-principle study, the metric outperformed conventional absolute methylation signatures in detecting early-stage breast and lung cancers.
More
-
Sep 16 |
Diagnostics World News | This week Mayo Clinic announced the launch of Precure, LLC, with founding partner Thermo Fisher Scientific. Precure will create one of the world’s leading biomedical datasets by integrating proteomic, genomic, and longitudinal clinical data to help researchers identify early biological signals of disease and provide a foundation for new discoveries in disease biology, diagnostics and therapeutics.
More
-
Sep 16 |
Diagnostics World | Since last year’s landmark legal ruling that the U.S. Food and Drug Administration’s attempted oversight of laboratory-developed tests was not supported by current legislation, the research-use-only (RUO) pathway has emerged as an increasingly attractive alternative to the FDA-regulated in vitro diagnostic (IVD) route for diagnostic companies. There’s nothing wrong with that, provided that analytical rigor and performance are not compromised throughout the development and validation processes.
More
-
Sep 11 |
Diagnostics World | As one of the highest-mortality cancers, pancreatic cancer has long been seen as a death sentence. But just in the past year we have witnessed exciting new study results bringing new hope. We can imagine adding years of productive life, or even curing disease completely. There is a way to achieve this, and it’s through early detection.
More
-
Sep 08 |
Diagnostics World | LinusBio, the company behind the hair-based autism test ClearStrand-ASD, is applying the same underlying technology to a new consumer product called Traced — a test that tracks a person's exposure to metals and other elements over roughly a month, rather than capturing a single snapshot in time.
More
-
Sep 03 |
Diagnostics World | Epigenetic methylation markers on your DNA can be used to predict your biological age, how soon you’ll die, or the development of various age-related diseases and morbidities. Researchers at the University of Southern California have extended these tests by looking at all of the gene transcription taking place as a function of each of five different popular clock predictors, increasing our understanding of the mechanisms.
More
-
Sep 02 |
Diagnostics World | Artificial intelligence can help reengineer pathology toward the point of care and provide guidance to first-on-the-scene responders, including those in military battlefields with no internet connectivity and limited medical training. The technological possibilities are driven largely by the data foundation that AI models learn from and analyze as well as institutions finding the “Goldilocks” speed at which to move on adoption that is neither reckless nor paralyzed by fear.
More
-
Sep 01 |
Diagnostics World | For decades now, doctors have been referring people suspected of having obstructive sleep apnea to a specialized medical facility for a polysomnogram (PSG). The gold-standard overnight test collects millions of data points from across the body, only a small subset of which gets prioritized for scoring the severity of the condition—notably, the apnea-hypopnea index (AHI) ranking how often their breathing slows or stops per hour of sleep.
More
-
Aug 26 |
Diagnostics World | Bios Life develops a predictive platform for cancer screening and surveillance; Dash Bio advances automated bioanalysis workflows; Bridge to Life expands its organ preservation technology for transplantation; and more.
More
-
Aug 25 |
Diagnostics World | HanchorBio and the research team led by Professor Sung-Liang Yu of National Taiwan University enter collaboration; NORD adds three new centers to its Rare Disease Centers of Excellence Network; NeuraLight announces that its platform will be deployed as part of the Healthy Brain Ageing study; and more.
More
-
Sep 24 |
Data shows priming agents improved sensitivity for disease detection and mutational profiling while preserving key cfDNA features.
More
-
Sep 24 |
Leading Phoenix urology practice adopts advanced AI cancer mapping to personalize surgical planning, enhance patient visualization, and pave the way for outpatient treatments
More
-
Sep 24 |
The expanded panel pairs the industry’s largest-ever marker count with methodology upgrades designed to give practitioners and patients the most comprehensive view of mold exposure yet, supporting more informed clinical decisions.
More
-
Sep 24 |
More
-
Sep 24 |
IQVIA MedTech is highlighting its Surgical Collaboration Platform, designed to help MedTech organizations coordinate and scale surgeon-to-surgeon education. The platform brings surgeon requests, credentialing, faculty matching, scheduling, documentation, training completion and reporting into a connected workflow as increasingly sophisticated medical technologies create greater demands on clinician education.
More
-
Sep 24 |
More
-
Sep 18 |
More
-
Sep 18 |
Reckitt plans to invest up to $600 million across New Jersey and North Carolina to strengthen U.S. R&D, innovation and OTC manufacturing. The investment will create a new science and innovation center and expand its largest U.S. OTC facility to support Mucinex, Move Free and future healthcare product demand.
More
-
Sep 18 |
More
-
Sep 16 |
IQVIA MedTech has launched Data Device Link (DDL), a new capability that connects patient-level data generated by medical devices and diagnostics with longitudinal healthcare data to provide a broader view of the patient journey. By linking device and diagnostic data with sources such as claims, prescriptions, laboratory data and electronic health records, DDL is designed to help manufacturers generate real-world evidence, evaluate outcomes and support regulatory and post-market research.
The announcement also highlights real-world applications of this approach, including the use of data linkage to address missing demographic information for an FDA representativeness assessment and the development of a post-market registry supporting five years of patient outcomes monitoring.
More
View more articles